ProPhase Labs, Inc.
PRPH
Rank in Stocks
#34079
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously... ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Share Price
$0.005525
Last synced: 2026-11-09
Market Cap
$77.44K
Change (1 day)
-44.75%
Change (1 year)
-99.80%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade ProPhase Labs, Inc. (PRPH)
Category
Healthcare
EPS for ProPhase Labs, Inc. (PRPH)
EPS as of June 2026 TTM: $-3.12
According to ProPhase Labs, Inc.'s latest financial reports, its current EPS (TTM) is $-3.12. At the end of 2025 the company had an EPS of $-1.74, an increase over its 2024 EPS of $-26.10.
EPS history for ProPhase Labs, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.12 | 79.31% |
| 2025 | $-1.74 | -93.33% |
| 2024 | $-26.10 | 166.33% |
| 2023 | $-9.80 | -183.76% |
| 2022 | $11.70 | 185.37% |
| 2021 | $4.10 | -305.00% |
| 2020 | $-2.00 | -23.08% |
| 2019 | $-2.60 | 73.33% |
| 2018 | $-1.50 | -105.75% |
| 2017 | $26.10 | -1,635.29% |
| 2016 | $-1.70 | -22.73% |
| 2015 | $-2.20 | -53.19% |
| 2014 | $-4.70 | -1,666.67% |
| 2013 | $0.30 | -140.82% |
| 2012 | $-0.74 | -59.17% |
| 2011 | $-1.80 | -28.00% |
| 2010 | $-2.50 | -16.67% |
| 2009 | $-3.00 | -30.23% |
| 2008 | $-4.30 | 126.32% |
| 2007 | $-1.90 | 35.71% |
| 2006 | $-1.40 | -150.00% |
| 2005 | $2.80 | 600.00% |
| 2004 | $0.40 | -33.33% |
| 2003 | $0.60 | -110.17% |
| 2002 | $-5.90 | -3,050.00% |
| 2001 | $0.20 | -104.08% |
| 2000 | $-4.90 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -308.38% |
DE
|
|
| $6.08 | -294.79% |
DE
|
|
| $1.55 | -149.70% |
JP
|
|
| $3.66 | -217.31% |
CH
|
|
| $0.45 | -114.42% |
IL
|
Questions about ProPhase Labs, Inc.'s earnings per share (EPS)
What is ProPhase Labs, Inc.'s earnings per share (EPS)?
ProPhase Labs, Inc.'s earnings per share (EPS) over the last twelve months is $-3.12, as of Jun 2026.
What was ProPhase Labs, Inc.'s earnings per share (EPS) in 2025?
In 2025, ProPhase Labs, Inc.'s earnings per share (EPS) was $-1.74, compared with $-26.10 in 2024.
How has ProPhase Labs, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, ProPhase Labs, Inc.'s earnings per share (EPS) was highest in 2022 ($11.70) and lowest in 2024 ($-26.10).
How does ProPhase Labs, Inc.'s earnings per share (EPS) compare with similar companies?
ProPhase Labs, Inc.'s earnings per share (EPS) ($-3.12) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.